Avelumab with axitinib for untreated advanced renal cell carcinoma (TA1120)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 January 2026
Suspected Cancer: recognition and referral (update)Status:In development | In consultationProgramme:NICE guidelineConsultation end date: 2 February 2026Expected publication date: 25 March 2026
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 8 December 2027
Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC